{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:12:37Z","timestamp":1793473957879,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.eururo.2011.03.054","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T19:01:22Z","timestamp":1302894082000},"page":"94-105","source":"Crossref","is-referenced-by-count":69,"title":["The Role of Antimuscarinics in the Management of Men With Symptoms of Overactive Bladder Associated With Concomitant Bladder Outlet Obstruction: An Update"],"prefix":"10.1016","volume":"60","author":[{"given":"Anastasios","family":"Athanasopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tubaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2011.03.054_bib0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0140-6736(91)90543-X","article-title":"High prevalence of benign prostatic hypertrophy in the community","volume":"338","author":"Garraway","year":"1991","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2011.03.054_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000049872","article-title":"Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH","volume":"40","author":"Bertaccini","year":"2001","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0015","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-5347(01)65075-4","article-title":"The International Continence Society \u201cBenign Prostatic Hyperplasia\u201d Study: the bothersomeness of urinary symptoms","volume":"157","author":"Peters","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.03.054_bib0025","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00345-009-0446-5","article-title":"Basic mechanisms of urgency: roles and benefits of pharmacotherapy","volume":"27","author":"Michel","year":"2009","journal-title":"World J Urol"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2011.03.054_bib0030","first-page":"S7","article-title":"Pathophysiology of overactive bladder and urge urinary incontinence","volume":"4","author":"Steers","year":"2002","journal-title":"Rev Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0035","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/j.amjmed.2005.12.010","article-title":"Pathophysiology of overactive bladder","volume":"119","author":"Chu","year":"2006","journal-title":"Amer J Med"},{"key":"10.1016\/j.eururo.2011.03.054_bib0445","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","article-title":"Antimuscarinic mechanisms and the overactive detrusor: an update","volume":"59","author":"Andersson","year":"2011","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2011.03.054_bib0045","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)01544-3","article-title":"Bladder afferents and their role in the overactive bladder","volume":"59","author":"Fowler","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.054_bib0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00192-006-0165-z","article-title":"Is sensory urgency part of the same spectrum of bladder dysfunction as detrusor overactivity?","volume":"18","author":"Haylen","year":"2007","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1016\/j.eururo.2011.03.054_bib0055","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1464-410X.2009.08361.x","article-title":"Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study","volume":"103","author":"Malone-Lee","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.054_bib0060","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","article-title":"A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0065","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0022-5347(01)62083-4","article-title":"Treatment choice for benign prostatic hyperplasia: a matter of urologic preference?","volume":"161","author":"Stoevelaar","year":"1999","journal-title":"J Urol"},{"issue":"Suppl 6","key":"10.1016\/j.eururo.2011.03.054_bib0070","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/nau.20487","article-title":"Lower urinary tract symptoms (LUTS) and bladder afferent activity","volume":"26","author":"Yoshimura","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.03.054_bib0075","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/nau.20743","article-title":"Proof of principle: the effect of antimuscarinics on bladder filling sensations in healthy subjects\u2014a placebo controlled double blind investigation using 4 and 8mg tolterodine extended release","volume":"29","author":"Mehnert","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.03.054_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0302-2838(02)00540-7","article-title":"Antimuscarinics and the overactive detrusor\u2014which is the main mechanism of action?","volume":"43","author":"Andersson","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0085","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/sj.bjp.0706780","article-title":"Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder","volume":"148","author":"Abrams","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0090","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0022-5347(17)44350-3","article-title":"Interaction between adrenergic and cholinergic nerve terminals in the urinary bladder of rabbit, cat and man","volume":"137","author":"Mattiasson","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0095","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/sj.bjp.0706297","article-title":"Distinct mixtures of muscarinic receptor subtypes mediate inhibition of noradrenaline release in different mouse peripheral tissues, as studied with receptor knockout mice","volume":"145","author":"Trendelenburg","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0100","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.eururo.2006.10.028","article-title":"Acetylcholine and molecular components of its synthesis and release machinery in the urothelium","volume":"51","author":"Lips","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1254\/jphs.FM0070115","article-title":"Basic and clinical aspects of non-neuronal acetylcholine: expression of non-neuronal acetylcholine in urothelium and its clinical significance","volume":"106","author":"Yoshida","year":"2008","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.eururo.2011.03.054_bib0110","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.juro.2007.03.006","article-title":"Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats","volume":"178","author":"Hedlund","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0115","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.juro.2010.03.104","article-title":"Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and\/or doxazosin in rats with or without partial urethral obstruction","volume":"184","author":"F\u00fcllhase","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.eururo.2007.12.007","article-title":"Cholinergic innervation and muscarinic receptors in the human prostate","volume":"54","author":"Witte","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2680.2000.00195.x","article-title":"The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies","volume":"20","author":"Pennefather","year":"2000","journal-title":"J Auton Pharmacol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0163-7258(02)00174-2","article-title":"Cholinergic innervation and function in the prostate gland","volume":"94","author":"Ventura","year":"2002","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.eururo.2011.03.054_bib0135","first-page":"1010","article-title":"Variation of M3 muscarinic receptor expression in different prostate tissues and its significance","volume":"30","author":"Song","year":"2009","journal-title":"Saudi Med J"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2011.03.054_bib0140","first-page":"S46","volume":"29","author":"Athanasopoulos","year":"2010","journal-title":"Antimuscarinics and bladder outlet obstruction: from a contraindication to an indication? Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.03.054_bib0145","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.urology.2006.03.006","article-title":"Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia","volume":"68","author":"Kaplan","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.054_bib0150","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1464-410X.2006.06068.x","article-title":"Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.054_bib0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/13685530903440408","article-title":"Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes","volume":"13","author":"Kaplan","year":"2010","journal-title":"Aging Male"},{"key":"10.1016\/j.eururo.2011.03.054_bib0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/nau.20586","article-title":"Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity","volume":"28","author":"Ronchi","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2011.03.054_bib0165","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S0090-4295(03)00588-0","article-title":"Positive response to ice water test associated with high-grade bladder outlet obstruction in patients with benign prostatic hyperplasia","volume":"62","author":"Hirayama","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.054_bib0170","first-page":"857","article-title":"Efficacy of treatment with propiverine hydrochloride in patients on lower urinary tract function\u2014BUP-4 tablets special study group II","volume":"12","author":"Nishimatsou","year":"1999","journal-title":"Jpn J Urol Surg"},{"key":"10.1016\/j.eururo.2011.03.054_bib0175","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","article-title":"Safety and tolerability of tolderodine for the treatment of overactive bladder in men with bladder outlet obstruction","volume":"175","author":"Abrams","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0180","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","article-title":"Tolderodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"174","author":"Kaplan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0185","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/00365590902836740","article-title":"Okayama Urological Research Group. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study","volume":"43","author":"Yokoyama","year":"2009","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0190","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolderodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2011.03.054_bib0195","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1569-9056(09)60460-7","article-title":"The Health Improvement Network (THIN) database: focused safety study of acute urinary retention (AUR) in men","volume":"8","author":"Rodriguez","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.03.054_bib0450","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1569-9056(09)60465-6","article-title":"The risk factors increasing post void residual urine volume after long term anticholinergics therapy over 1 year in patients with benign prostatic hyperplasia accompanied with overactive bladder","volume":"8","author":"Sung Yong","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.03.054_bib0205","first-page":"323","article-title":"Current role for combination therapy in male LUTS","volume":"63","author":"Chung","year":"2010","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0210","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1464-410X.1994.tb07477.x","article-title":"The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia","volume":"73","author":"Chapple","year":"1994","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0215","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/01.ju.0000067541.73285.eb","article-title":"Combination treatment with an a-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled study","volume":"169","author":"Athanasopoulos","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0220","first-page":"525","article-title":"A comparative study of the efficacy and safety of tamsulosin hydrochloride alone and combination of propiverine hydrochloride and tamsulosin hydrochloride in the benign prostatic hypertrophy with pollakisuria and\/or urinary incontinence","volume":"8","author":"Saito","year":"1999","journal-title":"Jpn J Urol Surg"},{"key":"10.1016\/j.eururo.2011.03.054_bib0225","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1464-410X.2005.5547_3.x","article-title":"Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder","volume":"95","author":"Athanasopoulos","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.054_bib0230","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/01.ju.0000173630.94559.fd","article-title":"Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign obstruction: a prospective, randomized, controlled multicenter study","volume":"174","author":"Lee","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0235","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.juro.2008.05.050","article-title":"Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms","volume":"180","author":"Rovner","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0240","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1464-410X.2008.07761.x","article-title":"Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score","volume":"102","author":"Kaplan","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.054_bib0245","first-page":"2","article-title":"Efficacy and safety of an alpha-blocker with and without anticholinergic agent in the management of lower urinary tract symptoms with detrusor overactivity","author":"Mohanty","year":"2009","journal-title":"UroToday Int J"},{"key":"10.1016\/j.eururo.2011.03.054_bib0250","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1442-2042.2006.01538.x","article-title":"Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study","volume":"13","author":"Maruyama","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0255","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00029330-200703010-00004","article-title":"Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study","volume":"120","author":"Yang","year":"2007","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.eururo.2011.03.054_bib0260","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4111\/kju.2009.50.11.1078","article-title":"The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms","volume":"50","author":"Kang","year":"2009","journal-title":"Korean J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0265","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","article-title":"Comparison of doxazosin with or without tolderodine in men with symptomatic bladder outlet obstruction and an overactive bladder","volume":"94","author":"Lee","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.054_bib0270","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4065\/83.9.1002","article-title":"Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study","volume":"83","author":"MacDiarmid","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eururo.2011.03.054_bib0275","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","article-title":"Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with \u03b1-blockers","volume":"56","author":"Chapple","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0280","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.juro.2009.08.023","article-title":"Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency","volume":"182","author":"Kaplan","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0285","first-page":"2","article-title":"Efficacy and tolerability of add-on trospium chloride in patients with benign prostate syndrome and overactive bladder: a non-interventional trial showing use of flexible dosing","author":"Wiedemann","year":"2009","journal-title":"UroToday Int J"},{"key":"10.1016\/j.eururo.2011.03.054_bib0290","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5336\/medsci.2008-8467","article-title":"Prospective comparison of two treatment modalities in benign prostate hyperplasia: alpha-blocker alone vs. alpha-blocker plus anticholinergic combination","volume":"30","author":"Aldemir","year":"2010","journal-title":"Turkiye Klinikleri J Med Sci"},{"key":"10.1016\/j.eururo.2011.03.054_bib0295","unstructured":"Suzuki Y, Takasaka S, Kishimoto K, et al. Combination treatment with an alpha1-blocker plus an anticholinergic for the patients with suspected bladder outlet obstruction (BOO) concomitant with over-active bladder (OAB). Abstract presented at: International Continence Society Annual Meeting; August 25\u201327, 2004; Paris, France."},{"key":"10.1016\/j.eururo.2011.03.054_bib0300","unstructured":"Lim E, Chia SJ. Combination therapy using alpha-blocker and antimuscarinic drugs in men with lower urinary tract symptoms suggestive of bladder outlet obstruction and an overactive bladder: is it safe and efficacious? Abstract presented at: International Continence Society Annual Meeting; August 28\u2013September 2, 2005; Montreal, Canada."},{"key":"10.1016\/j.eururo.2011.03.054_bib0305","doi-asserted-by":"crossref","unstructured":"Kaplan SA, Zoltan E, Te AE. Safety and efficacy of tolterodine, solifenacin, and darifenacin in men with lower urinary tract symptoms (LUTS) on alpha-blockers with persistent overactive bladder symptoms. Abstract presented at: American Urological Association Annual Meeting; May 17\u201322, 2008; Orlando, FL, USA.","DOI":"10.1016\/S0022-5347(08)62044-3"},{"key":"10.1016\/j.eururo.2011.03.054_bib0310","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.urology.2009.12.010","article-title":"Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams","volume":"75","author":"Chung","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.054_bib0315","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1517\/14740338.7.4.473","article-title":"Safety of anticholinergics in patients with benign prostatic hyperplasia","volume":"7","author":"Athanasopoulos","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.eururo.2011.03.054_bib0320","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1464-410X.2009.09008.x","article-title":"Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction","volume":"106","author":"F\u00fcllhase","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.054_bib0325","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1569-9056(09)60466-8","article-title":"Study of safety and urodynamic characterization of treatment with tamsulosin, tolderodine and tamsulosin plus tolderodine, in men with LUTS","volume":"8","author":"Conde-Santos","year":"2009","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.03.054_bib0330","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1742-1241.2008.01849.x","article-title":"Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin","volume":"62","author":"Kay","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2011.03.054_bib0335","unstructured":"Chapple C, Billington A, Jeachins P, et al. The management of lower urinary tract symptoms in men. Report of National Institute for Health and Clinical Excellence (NICE). NICE Web site. http:\/\/www.nice.org.uk\/nicemedia\/live\/12984\/48556\/48556.pdf."},{"key":"10.1016\/j.eururo.2011.03.054_bib0340","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.eururo.2008.11.028","article-title":"Editorial comment on: tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with \u03b1-blockers","volume":"56","author":"Speakman","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0345","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.eururo.2008.11.027","article-title":"Editorial comment on: tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with \u03b1-blockers","volume":"56","author":"Dmochowski","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0350","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2008.06.032","article-title":"Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size","volume":"55","author":"Roehrborn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0355","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.urology.2008.06.067","article-title":"Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB","volume":"72","author":"Roehrborn","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.054_bib0360","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1464-410X.2010.09359.x","article-title":"Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an alpha-blocker: effect of baseline prostate-specific antigen concentration","volume":"106","author":"Chapple","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2011.03.054_bib0365","first-page":"73","article-title":"Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms","volume":"9","author":"Kaplan","year":"2007","journal-title":"Rev Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0370","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOU.0b013e328333ac68","article-title":"Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia","volume":"20","author":"Wang","year":"2010","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0375","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1464-410X.2010.09205.x","article-title":"A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder","volume":"106","author":"Giuliano","year":"2010","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2011.03.054_bib0380","first-page":"S292","article-title":"Differences in the actions of the M3-antagonist tolterodine and the beta 3 adrenoceptor agonist mirabegron on non-voiding activity in rats with partial outflow obstruction [abstract]","volume":"21","author":"Gillespie","year":"2010","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.eururo.2011.03.054_bib0385","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.urology.2007.01.059","article-title":"Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines","volume":"69","author":"Badawi","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2011.03.054_bib0390","first-page":"239","article-title":"Clinical proof of concept study (BLOSSOM) shows novel \u03b23 adrenoreceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder","volume":"7","author":"Chapple","year":"2008","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.03.054_bib0395","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1569-9056(10)60758-0","article-title":"Dose-ranging study of once-daily mirabegron (YM178), a novel selective \u03b23-adrenoreceptor agonist, with overactive bladder (OAB)","volume":"9","author":"Chapple","year":"2010","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2011.03.054_bib0400","first-page":"85","article-title":"The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"99","author":"Blake-James","year":"2006","journal-title":"BIU Int"},{"key":"10.1016\/j.eururo.2011.03.054_bib0405","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2006.07.017","article-title":"Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review","volume":"50","author":"Novara","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0410","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1517\/14656566.6.14.2429","article-title":"Efficacy of the combination of an alpha1-blocker with an anticholinergic in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction","volume":"6","author":"Athanasopoulos","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.eururo.2011.03.054_bib0415","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1097\/01.ju.0000176460.62847.23","article-title":"Combined use of alpha-adrenergic and muscarinic antagonist for the treatment of voiding dysfunction","volume":"174","author":"Ruggieri","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0420","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11934-008-0047-7","article-title":"Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia","volume":"9","author":"MacDiarmid","year":"2008","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2011.03.054_bib0425","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ucl.2006.06.013","article-title":"When to use antimuscarinics in men who have lower urinary tract symptoms","volume":"33","author":"Lee","year":"2006","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2011.03.054_bib0430","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11934-006-0055-4","article-title":"Antimuscarinic therapy in men with lower urinary tract symptoms: what is the evidence?","volume":"7","author":"Dmochowski","year":"2006","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2011.03.054_bib0435","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00042307-200401000-00003","article-title":"Does anticholinergic medication have a role for men with lower urinary tract symptoms\/benign prostatic hyperplasia either alone or in combination with other agents?","volume":"14","author":"Reynard","year":"2004","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2011.03.054_bib0440","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MOU.0b013e3283330862","article-title":"Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia","volume":"20","author":"Chapple","year":"2010","journal-title":"Curr Opin Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811003617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283811003617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T05:35:40Z","timestamp":1712381740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283811003617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0302283811003617"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2011.03.054","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}